Index - 2021

2021 / 2020 / 2019 / 2018



  • Overig
  • Thema-artikelH
  • Let op!LO
  • Nieuw
A
Ad26.COV2-S-vaccin AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 AIS CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 Aktiprol® amisulpride 202121-28 antipsychotica 202121-28 bijwerkingen 202121-28 meta-analyse 202121-28 netwerk meta-analyse 202121-28 amisulpride Aktiprol® 202121-28 antipsychotica 202121-28 bijwerkingen 202121-28 meta-analyse 202121-28 netwerk meta-analyse 202121-28 amputatie canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 angina CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 antipsychotica Aktiprol® 202121-28 amisulpride 202121-28 bijwerkingen 202121-28 meta-analyse 202121-28 netwerk meta-analyse 202121-28 aritmie atrium flutter 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 screening 202117-20 AstraZenica Ad26.COV2-S-vaccin 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 atrium flutter aritmie 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 screening 202117-20 atriumfibrilleren aritmie 202117-20 atrium flutter 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 screening 202117-20
B
baarmoederhalskanker AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 bamlanivimab SARS-CoV-2 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 beroerte CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 beschermingsduur COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 bijwerkingen Aktiprol® 202121-28 EMA 202157-62 FDA 202157-62 amisulpride 202121-28 antipsychotica 202121-28 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 epidemiologisch onderzoek 20215-7 gerandomiseerd onderzoek 202157-62 meta-analyse 202121-28 myocardinfarct 202157-62 netwerk meta-analyse 202121-28 observationeel onderzoek 202157-62 post-marketing surveillance 20215-7 registratie 202157-62 registratieonderzoek 20215-7 richtlijnen 202157-62 rosiglitazon 202157-62 vaccins 20215-7 vaccinvigilantie 20215-7 bivalent AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 bloedglucoseverlagende middel EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62
C
canagliflozine amputatie 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 canakinumab MACE 2021 cardiovasculaire mortaliteit 2021 colchicine 2021 coronaire hartziekten 2021 in-stent-restenose 2021 myocardinfarct 2021 secundaire preventie 2021 stents 2021 CanSino Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 cardiovasculair CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 cardiovasculaire mortaliteit MACE 2021 canakinumab 2021 colchicine 2021 coronaire hartziekten 2021 in-stent-restenose 2021 myocardinfarct 2021 secundaire preventie 2021 stents 2021 casirivimab SARS-CoV-2 2021 bamlanivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 cerebrovasculair CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 Cervarix AIS 202147-56 CRPS 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 cervixcarcinoom AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 ChAdOx1-S-vaccin Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 clopidogrel CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 colchicine MACE 2021 canakinumab 2021 cardiovasculaire mortaliteit 2021 coronaire hartziekten 2021 in-stent-restenose 2021 myocardinfarct 2021 secundaire preventie 2021 stents 2021 Comirnaty COVID-19 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 coronaire hartziekten MACE 2021 canakinumab 2021 cardiovasculaire mortaliteit 2021 colchicine 2021 in-stent-restenose 2021 myocardinfarct 2021 secundaire preventie 2021 stents 2021 corticosteroïden COVID-19 202163-68 SARS-CoV-2 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 interleukine-6-antagonist 202163-68 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 covid Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 COVID-19 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 SARS-CoV-2 202163-68 beschermingsduur 202113-16 corticosteroïden 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 doelgroep 202113-16 interleukine-6-antagonist 202163-68 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 zuurstoftherapie 202163-68 covid-19 Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 SARS-CoV-2 2021 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 bamlanivimab 2021 casirivimab 2021 covid 202129-34 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 202129-34 pandemie 2021 regdanvimab 2021 sotrovimab 2021 vaccin 202129-34 covidpandemie SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 covidpatiënten SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 covidpneumonie COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 dexamethason 202163-68 interleukine-6-antagonist 202163-68 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 CRPS AIS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 CVA LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 CYP2C19 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 cytochroom P450 CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12
D
dapagliflozine amputatie 202141-46 canagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 dexamethason COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 covidpneumonie 202163-68 interleukine-6-antagonist 202163-68 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 diabetes EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 diabetes mellitus type 2 amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 doelgroep COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16
E
EGFR-tyrokinaseremmer Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 EMA FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 empagliflozine amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 epidemiologisch onderzoek bijwerkingen 20215-7 post-marketing surveillance 20215-7 registratieonderzoek 20215-7 vaccins 20215-7 vaccinvigilantie 20215-7 epidermale groeifactorreceptor EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 Erlotinib EGFR-tyrokinaseremmer 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 ertugliflozine amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 etesevimab SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 extramurale behandeling EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 ezetimib CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4
F
FDA EMA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62
G
gangreen van Fournier amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 Gardasil AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 genotypering CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 gerandomiseerd onderzoek EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 glucosespiegel amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46
H
hartfalen amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 hartritmestoornis aritmie 202117-20 atrium flutter 202117-20 atriumfibrilleren 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 screening 202117-20 hba1c amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 hersenbloeding CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 herseninfarct CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 HPV AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 humaan papillomavirus AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56
I
imdevimab SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 immuungecompromitteerden SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 in-stent-restenose MACE 2021 canakinumab 2021 cardiovasculaire mortaliteit 2021 colchicine 2021 coronaire hartziekten 2021 myocardinfarct 2021 secundaire preventie 2021 stents 2021 interleukine-6-antagonist COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 intermediate metabolizer CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12
J
Janssen Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34
K
keto-acidose amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46
L
LDL-cholesterol CVA 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 leverenzymen CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 longcovid SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021
M
MACE canakinumab 2021 cardiovasculaire mortaliteit 2021 colchicine 2021 coronaire hartziekten 2021 in-stent-restenose 2021 myocardinfarct 2021 secundaire preventie 2021 stents 2021 medisch hulpmiddel aritmie 202117-20 atrium flutter 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medische app 202117-20 screening 202117-20 medische app aritmie 202117-20 atrium flutter 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 screening 202117-20 messenger-RNA COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 meta-analyse Aktiprol® 202121-28 amisulpride 202121-28 antipsychotica 202121-28 bijwerkingen 202121-28 netwerk meta-analyse 202121-28 metformine amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 Moderna COVID-19 202113-16 Comirnaty 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 monoklonale antilichamen SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 mRNA COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 myocardinfarct CVA 20211-4 EMA 202157-62 FDA 202157-62 LDL-cholesterol 20211-4 MACE 2021 TIA 20211-4 angina 20211-4 beroerte 20211-4 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 canakinumab 2021 cardiovasculair 20211-4 cardiovasculaire mortaliteit 2021 cerebrovasculair 20211-4 colchicine 2021 coronaire hartziekten 2021 diabetes 202157-62 ezetimib 20211-4 gerandomiseerd onderzoek 202157-62 hersenbloeding 20211-4 herseninfarct 20211-4 in-stent-restenose 2021 observationeel onderzoek 202157-62 registratie 202157-62 revascularisatie 20211-4 richtlijnen 20211-4 richtlijnen 202157-62 rosiglitazon 202157-62 secundaire preventie 2021 statinen 20211-4 stents 2021 streefwaarden 20211-4
N
netwerk meta-analyse Aktiprol® 202121-28 amisulpride 202121-28 antipsychotica 202121-28 bijwerkingen 202121-28 meta-analyse 202121-28 neutraliserende monoklonale antilichamen SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 sotrovimab 2021 niet-kleincellig longcarcinoom EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 overleving 202135-40 progressievrij 202135-40 nonavalent AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 NSCLC EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40
O
observationeel onderzoek EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 registratie 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 overleving EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 progressievrij 202135-40
P
P2Y12-remmers CYP2C19 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 pandemie Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 COVID-19 202113-16 COVID-19 202163-68 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Comirnaty 202113-16 Janssen 202129-34 Moderna 202113-16 SARS-CoV-2 202113-16 SARS-CoV-2 202163-68 SARS-CoV-2 2021 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 bamlanivimab 2021 beschermingsduur 202113-16 casirivimab 2021 corticosteroïden 202163-68 covid 202129-34 covid-19 202129-34 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 covidpneumonie 202163-68 dexamethason 202163-68 doelgroep 202113-16 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 interleukine-6-antagonist 202163-68 longcovid 2021 mRNA 202113-16 messenger-RNA 202113-16 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 regdanvimab 2021 sarilumab 202163-68 sotrovimab 2021 tocilizumab 202163-68 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 vaccin 202129-34 virusmutatie 202113-16 zuurstoftherapie 202163-68 PCI CYP2C19 20219-12 P2Y12-remmers 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 percutane coronaire interventie CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 poor metabolizer CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 post-marketing surveillance bijwerkingen 20215-7 epidemiologisch onderzoek 20215-7 registratieonderzoek 20215-7 vaccins 20215-7 vaccinvigilantie 20215-7 POTS AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56 prasugrel CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 progressievrij EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 Tarceva® 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40
Q
quadrivalent AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 vaccinatie 202147-56 vermoeidheidssyndroom 202147-56
R
regdanvimab SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 sotrovimab 2021 registratie EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 richtlijnen 202157-62 rosiglitazon 202157-62 registratieonderzoek bijwerkingen 20215-7 epidemiologisch onderzoek 20215-7 post-marketing surveillance 20215-7 vaccins 20215-7 vaccinvigilantie 20215-7 revascularisatie CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 richtlijnen CVA 20211-4 EMA 202157-62 FDA 202157-62 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 cardiovasculair 20211-4 cerebrovasculair 20211-4 diabetes 202157-62 ezetimib 20211-4 gerandomiseerd onderzoek 202157-62 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 revascularisatie 20211-4 rosiglitazon 202157-62 statinen 20211-4 streefwaarden 20211-4 rosiglitazon EMA 202157-62 FDA 202157-62 bijwerkingen 202157-62 bloedglucoseverlagende middel 202157-62 diabetes 202157-62 gerandomiseerd onderzoek 202157-62 myocardinfarct 202157-62 observationeel onderzoek 202157-62 registratie 202157-62 richtlijnen 202157-62
S
sarilumab COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 interleukine-6-antagonist 202163-68 pandemie 202163-68 tocilizumab 202163-68 zuurstoftherapie 202163-68 SARS-CoV-2 COVID-19 202113-16 COVID-19 202163-68 Comirnaty 202113-16 Moderna 202113-16 bamlanivimab 2021 beschermingsduur 202113-16 casirivimab 2021 corticosteroïden 202163-68 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 covidpneumonie 202163-68 dexamethason 202163-68 doelgroep 202113-16 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 interleukine-6-antagonist 202163-68 longcovid 2021 mRNA 202113-16 messenger-RNA 202113-16 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 202113-16 pandemie 202163-68 pandemie 2021 regdanvimab 2021 sarilumab 202163-68 sotrovimab 2021 tocilizumab 202163-68 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 zuurstoftherapie 202163-68 screening aritmie 202117-20 atrium flutter 202117-20 atriumfibrilleren 202117-20 hartritmestoornis 202117-20 medisch hulpmiddel 202117-20 medische app 202117-20 secundaire preventie MACE 2021 amputatie 202141-46 canagliflozine 202141-46 canakinumab 2021 cardiovasculaire mortaliteit 2021 colchicine 2021 coronaire hartziekten 2021 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 in-stent-restenose 2021 keto-acidose 202141-46 metformine 202141-46 myocardinfarct 2021 sglt-2-remmers 202141-46 stents 2021 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 sglt-2-remmers amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sulfonylureumderivaten 202141-46 urineweginfecties 202141-46 sotrovimab SARS-CoV-2 2021 bamlanivimab 2021 casirivimab 2021 covid-19 2021 covidpandemie 2021 covidpatiënten 2021 etesevimab 2021 imdevimab 2021 immuungecompromitteerden 2021 longcovid 2021 monoklonale antilichamen 2021 neutraliserende monoklonale antilichamen 2021 pandemie 2021 regdanvimab 2021 Sputnik Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 statinen CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 streefwaarden 20211-4 stentplaatsing CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stents 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 stents CYP2C19 20219-12 MACE 2021 P2Y12-remmers 20219-12 PCI 20219-12 canakinumab 2021 cardiovasculaire mortaliteit 2021 clopidogrel 20219-12 colchicine 2021 coronaire hartziekten 2021 cytochroom P450 20219-12 genotypering 20219-12 in-stent-restenose 2021 intermediate metabolizer 20219-12 leverenzymen 20219-12 myocardinfarct 2021 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 secundaire preventie 2021 stentplaatsing 20219-12 ticagrelor 20219-12 tromboseprofylaxe 20219-12 streefwaarden CVA 20211-4 LDL-cholesterol 20211-4 TIA 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 sulfonylureumderivaten amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 urineweginfecties 202141-46
T
Tarceva® EGFR-tyrokinaseremmer 202135-40 Erlotinib 202135-40 NSCLC 202135-40 epidermale groeifactorreceptor 202135-40 extramurale behandeling 202135-40 niet-kleincellig longcarcinoom 202135-40 overleving 202135-40 progressievrij 202135-40 TIA CVA 20211-4 LDL-cholesterol 20211-4 angina 20211-4 beroerte 20211-4 cardiovasculair 20211-4 cerebrovasculair 20211-4 ezetimib 20211-4 hersenbloeding 20211-4 herseninfarct 20211-4 myocardinfarct 20211-4 revascularisatie 20211-4 richtlijnen 20211-4 statinen 20211-4 streefwaarden 20211-4 ticagrelor CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 tromboseprofylaxe 20219-12 tocilizumab COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 interleukine-6-antagonist 202163-68 pandemie 202163-68 sarilumab 202163-68 zuurstoftherapie 202163-68 tozinameran COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16 virusmutatie 202113-16 tromboseprofylaxe CYP2C19 20219-12 P2Y12-remmers 20219-12 PCI 20219-12 clopidogrel 20219-12 cytochroom P450 20219-12 genotypering 20219-12 intermediate metabolizer 20219-12 leverenzymen 20219-12 percutane coronaire interventie 20219-12 poor metabolizer 20219-12 prasugrel 20219-12 stentplaatsing 20219-12 stents 20219-12 ticagrelor 20219-12
U
uitwisselbaarheid COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 vaccin 202113-16 virusmutatie 202113-16 urineweginfecties amputatie 202141-46 canagliflozine 202141-46 dapagliflozine 202141-46 diabetes mellitus type 2 202141-46 empagliflozine 202141-46 ertugliflozine 202141-46 gangreen van Fournier 202141-46 glucosespiegel 202141-46 hartfalen 202141-46 hba1c 202141-46 keto-acidose 202141-46 metformine 202141-46 secundaire preventie 202141-46 sglt-2-remmers 202141-46 sulfonylureumderivaten 202141-46
V
vaccin Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 COVID-19 202113-16 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Comirnaty 202113-16 Janssen 202129-34 Moderna 202113-16 SARS-CoV-2 202113-16 Sputnik 202129-34 Vaxzevria® 202129-34 Vectorvaccins 202129-34 beschermingsduur 202113-16 covid 202129-34 covid-19 202129-34 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 pandemie 202129-34 tozinameran 202113-16 uitwisselbaarheid 202113-16 virusmutatie 202113-16 vaccinatie AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vermoeidheidssyndroom 202147-56 vaccins bijwerkingen 20215-7 epidemiologisch onderzoek 20215-7 post-marketing surveillance 20215-7 registratieonderzoek 20215-7 vaccinvigilantie 20215-7 vaccinvigilantie bijwerkingen 20215-7 epidemiologisch onderzoek 20215-7 post-marketing surveillance 20215-7 registratieonderzoek 20215-7 vaccins 20215-7 Vaxzevria® Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vectorvaccins 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 Vectorvaccins Ad26.COV2-S-vaccin 202129-34 AstraZenica 202129-34 CanSino 202129-34 ChAdOx1-S-vaccin 202129-34 Janssen 202129-34 Sputnik 202129-34 Vaxzevria® 202129-34 covid 202129-34 covid-19 202129-34 pandemie 202129-34 vaccin 202129-34 vermoeidheidssyndroom AIS 202147-56 CRPS 202147-56 Cervarix 202147-56 Gardasil 202147-56 HPV 202147-56 POTS 202147-56 baarmoederhalskanker 202147-56 bivalent 202147-56 cervixcarcinoom 202147-56 humaan papillomavirus 202147-56 nonavalent 202147-56 quadrivalent 202147-56 vaccinatie 202147-56 virusmutatie COVID-19 202113-16 Comirnaty 202113-16 Moderna 202113-16 SARS-CoV-2 202113-16 beschermingsduur 202113-16 doelgroep 202113-16 mRNA 202113-16 messenger-RNA 202113-16 pandemie 202113-16 tozinameran 202113-16 uitwisselbaarheid 202113-16 vaccin 202113-16
Z
zuurstoftherapie COVID-19 202163-68 SARS-CoV-2 202163-68 corticosteroïden 202163-68 covidpneumonie 202163-68 dexamethason 202163-68 interleukine-6-antagonist 202163-68 pandemie 202163-68 sarilumab 202163-68 tocilizumab 202163-68